Kasper D, Braunwald E, Hauser S, Jameson J, Fauci A, Longo D. Principles of internal medicine 16th edition. McGraw Hill Medical Publishing Division, USA; 2005.

Özge A, Şaşmaz T, Buğdaycı R, Cakmak S, Kurt A, Kaleağası S, et al. The prevalence of chronic and episodic migraine in children and adolescents. European journal of neurology. 2013;20(1):95-101.

Mirzaei G-r. A review of cammon migraine in girls high school and related fall in education in Shahrekord region. Journal of Shahrekord University of Medical Sciences. 2004;5(4):55-62.

Ghayeghran A, Sh FS. Prevalence of migraine in schoolchildren in Rasht. Journal of Guilan University of Medical Sciences. 2004;50:22-6.

Moaiedi A, Boroomand S. Causes of headache in patients referring to Bandar Abbas pediatric hospital. Bimonthly Journal of Hormozgan University of Medical Sciences. 2004;8(2):73-6.

Amiri Parsa T, Khademosharie M, Hamedinia M, Azarnive M. Evaluation of the Factors Associated with Overweight and Obesity in 30-to 50-year-old Women of Sabzevar. Iranian Journal of Epidemiology. 2014;9(4):75-83.

Khazaie T, Dehghany M, Sharifzadeh G, Reyasie H, Phani J, Usefi H. Evaluation of the Factors Associated with Overweight and Obesity in 30-to 50-year-old Women of Sabzevar. Iranian Journal of Epidemiology. 2014;10(1):73-80.

Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part two. Journal of Pediatric Health Care. 2008;22(1):52-9.

Bahrami P. Incidence of Migraine in high school students in Khorramabad. 2005.

Ayatollahi S, Khosravi A. A case-control study of migraine and tension-type headache’s risk factors among Shiraz schoolchildren. Scientific Journal of Hamadan University of Medical Sciences. 2005;11(4):37-42.

Zamani G, Ghofrani M. Prophylactic sodium valproate and propranolol in childhood migraine: a randomized clinical trial. Tehran University Medical Journal TUMS Publications. 2006;64(4):69-77.

Fallah R, Divanizadeh M, Karimi M, Ordooei M. Evaluation of Efficacy and Safety of Propranolol for Pediatric Migraine Prophylaxis. SSU_Journals. 2013;21(1):94-100.

Fallahzade H, Alihaydari A, Hoseini H. Prevalence of migraine and tension headache in students of guidance schools in Yazd city, 2008. Razi Journal of Medical Sciences. 2010;17(76):52-61.

Solomon GD. The Practicing Physicians Approach to Headache. The Clinical Journal of Pain. 1992;8(4):370.

Seyed mohamad taghi A, Khosravi A. Prevalence of migraine and tension headache and its correlates in primary school students of Shiraz. 2005;8(1):78-85.

Taghdiri M, Razavi Z. Comparison of the therapeutic effects and side effects of sodium valproate and propranolol in preventing migraine headaches in children. Scientific Journal of Hamadan University of Medical Sciences2004;11(2):38-42.

Hershey AD, Winner PK. Pediatric migraine: recognition and treatment. The Journal of the American Osteopathic Association. 2005;105(4_suppl):2S-8S.

Magis D, Schoenen J. Treatment of migraine: update on new therapies. Current opinion in neurology. 2011;24(3):203-10.

Mousavi sa, Zarea m, Mirboud sm. The comparison of the effects of both propranolol and transcutaneous electrical nerve stimulation in prevention of migraine headache. Journal of Shahrekord Uuniversity of Medical Sciences. 2005;7(3):75-9.

Omid Y, Nasiri J, Nasr IP. Study of sodium valproate's side effects in 2 to 15-year-old children withepilepsy or migraine disorders. Journal of isfahan medical school. 2016;34(387):707-11.

Motamedi M, Ghini MR, Etemadi P, Ramim T. Levetiracetam and lamotrigine in old aged onset of epilepsy: a randomized double-blind clinical trial. Tehran University Medical Journal TUMS Publications. 2013;71(9):568-76.

Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache: The Journal of Head and Face Pain. 2004;44(3):238-43.

Pakalnis A, Kring D, Meier L. Levetiracetam Prophylaxis in Pediatric Migraine—An Open‐Label Study. Headache: The Journal of Head and Face Pain. 2007;47(3):427-30.

Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura A triple‐blind, placebo‐controlled crossover study. Neurology. 1994;44(4):647-.

Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache: The Journal of Head and Face Pain. 2000;40(8):672-6.

Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the Management of Recurrent Migraine: A Meta‐analytic Review. Headache: The Journal of Head and Face Pain. 1991;31(5):333-40.

Kozubski W, Prusiński A. Sodium valproate versus propranolol in the prophylactic treatment of migraine. Neurologia i neurochirurgia polska. 1995;29(6):937-47.

Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Archives of neurology. 1997;54(9):1141-5.

Firidis A, Kaube H. Prophylactic therapy for migraine. Cur Treat Option Neurol2003; 5: 431-40. 13. Nutia A, Lucetti C. Longterm follow-up after nimodipine discontinuation. J Neurology. 1996;16(5):43-7.

Bromfield EB, Dworetzky BA, Wyszynski DF, Smith CR, Baldwin EJ, Holmes LB. Valproate teratogenicity and epilepsy syndrome. Epilepsia. 2008;49(12):2122-4.

Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert opinion on drug safety. 2005;4(2):345-53.

Lindholm D. Levetiracetam levels correlating with successful treatment of epilepsy, headaches, cognitive effects, and adverse reactions in pediatric age group. Epilepsia. 2002;43:60.

Verma A, Srivastava D, Kumar A, Singh V. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in Northern India. Clinical neuropharmacology. 2013;36(6):193-7.

Sadeghian H, Motiei-Langroudi R. Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study. Annals of Indian Academy of Neurology. 2015;18(1):45.

Landmark CJ. Antiepileptic drugs in non-epilepsy disorders. CNS drugs. 2008;22(1):27-47.

Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clinical neuropharmacology. 2006;29(6):338-42.

Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. Levetiracetam in the preventive treatmentof transformed migraine: A prospective, open-label, pilot study. Current therapeutic research. 2005;66(3):212-21.

Homam M, Farajpour A, Khadem S, Mostafavian Z. The Experiential Comparison of Levetiracetam Efficacy in Migraine Headache with Sodium Valproate. Caspian Journal of Neurological Sciences. 2016;2(5):42-9.

Awaad Y, Rizk T. Levetiracetam in the treatment of pediatric headache. Journal of Taibah University Medical Sciences. 2014;9(1):74-7

Ben-Menachem E, Edrich P, Van Vleymen B, Sander JW, Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy research. 2003;53(1):57-64.

Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9(2):80-7.

Miller GS. Pyridoxine ameliorates adverse behavioral effects of levetiracetam in children. Epilepsia. 2002;43:62.

Gates JR, Folland C, Ankenbauer JL, Moriarty GL, Penovich PE. Behavioral side effects of levetiracetam. Epilepsia. 2002;43(Suppl 7):187.

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. The Cochrane Library. 2013.